Designated SMPs as enclosed
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aarti Pharmalabs reported FY26 standalone revenue of Rs 1,797.55 crore, nearly flat versus FY25's Rs 1,771.35 crore. However, profit before tax declined sharply to Rs 234.24 crore from Rs 336.34 crore (~30% fall), and net profit fell to Rs 176.20 crore from Rs 257.35 crore (~32% decline). EPS dropped to Rs 19.44 from Rs 28.39. The company recognized a Rs 29.75 crore exceptional charge for new labour code provisions and a Rs 29.73 crore fair value loss on a foreign exchange derivative contract that was omitted from prior periods' calculations. Q3 FY26 figures were restated to reflect this correction. Consolidated revenue declined to Rs 1,819.44 crore from Rs 2,115.07 crore, partly due to Ganesh Polychem becoming a joint venture from April 2025 making numbers non-comparable. Board declared Rs 2 per share (40%) final dividend and appointed two senior management personnel. Auditors issued unmodified opinion with emphasis of matter on the derivative restatement.
Significant profit decline and accounting restatement may create near-term volatility despite dividend declaration. The derivative omission from prior periods raises concerns about internal controls, though the impact is now fully recognized and audited.